NCT00637091View on ClinicalTrials.gov

Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2011

Conditions
Advanced Colorectal Cancer
Interventions
DRUG

Cetuximab, irinotecan

cetuximab, irinotecan

Trial Locations (1)

138736

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER